Afinitor®
Advanced RCC
AFINITOR is a once-daily oral inhibitor of mTOR (mammalian target of rapamycin) for patients with advanced renal cell carcinoma (RCC) whose disease has progressed on or after treatment with VEGF-targeted therapy.
This information is based on the European Summary of Product Characteristics. The prescribing information in your country may vary; please consult your local prescribing information and/or contact your local Novartis representative.
www.afinitor.com/global »
(For Non U.S. Health Care Professionals Only)
www.afinitor.com/advanced-renal-cell-carcinoma/hcp/index.jsp »
(For U.S. Health Care Professionals Only)
www.afinitor.com »
(For U.S. Residents Only)